Acute Sinusitis Treatment Market Share

Regionally, the global acute sinusitis market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America is predicted to hold largest revenue share by 2036, on the back of high prevalence of sinusitis in the region. Over 28 million adults were diagnosed with sinusitis in the United States, in 2020. Moreover, the increasing government investment in healthcare sector and favorable medical reimbursement policies are estimated to boost the regional market growth. According to the World Health Organization (WHO), as of 2018, 16.416 % of the GDP was spent on the healthcare sector in North America.

APAC Market Analysis

The acute sinusitis market in the Asia Pacific is estimated to witness notable growth over the forecast period accounting to the increasing cases of respiratory diseases, due to the increasing pollution in major cities, such as, Shanghai, Hotan, Delhi, Kathmandu, and Kabul, among others. Moreover, increasing investment in public healthcare system is estimated to boost the market growth in the region.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of acute sinusitis is estimated at USD 2.37 billion.

Acute Sinusitis Market size was over USD 2.24 billion in 2023 and is anticipated to reach USD 5.6 billion by 2036, growing at around 7.3% CAGR during the forecast period i.e., between 2024-2036. Rising prevalence of sinusitis and growing R&D investment for medical research will impel the market growth.

North America is predicted to hold largest revenue share by 2036, on the back of high prevalence of sinusitis in the region.

The major players in the market are Novartis AG, F. Hoffmann-La Roche Ltd., Amgen Inc., Cerecor, Inc., Bausch Health Companies Inc., and others.

Acute Sinusitis Treatment Market Share